Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Employees - 7, CEO - Jeffrey A. Meckler, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -22.78, Piotroski Score(max is 10): 3, Working Capital: $-2099505, Total Assets: $6839207, Retained Earnings: $-70200532, EBIT: -17115102, Total Liabilities: $8512563, Revenue: $1470

AryaFin Target Price - $0.6 - Current Price $ - Analyst Target Price $